Share on StockTwits

Shares of Alkermes Plc (NASDAQ:ALKS) have been given an average rating of “Buy” by the nine brokerages that are presently covering the stock, Stock Ratings Network.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $48.50.

In other Alkermes Plc news, CFO James M. Frates sold 15,000 shares of Alkermes Plc stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $41.37, for a total transaction of $620,550.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on ALKS shares. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Wednesday, August 6th. They now have a $45.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Alkermes Plc from $57.00 to $56.00 in a research note on Friday, August 1st. Finally, analysts at Mizuho cut their price target on shares of Alkermes Plc from $61.00 to $59.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock.

Shares of Alkermes Plc (NASDAQ:ALKS) traded down 1.39% on Friday, hitting $42.54. 34,522 shares of the company’s stock traded hands. Alkermes Plc has a 52-week low of $29.36 and a 52-week high of $54.25. The stock’s 50-day moving average is $44.91 and its 200-day moving average is $46.50. The company’s market cap is $6.203 billion.

Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Thursday, July 31st. The company reported $0.11 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.14 by $0.03. The company had revenue of $153.40 million for the quarter, compared to the consensus estimate of $146.91 million. During the same quarter last year, the company posted $0.30 earnings per share. Alkermes Plc’s revenue was up 10.7% compared to the same quarter last year. Analysts expect that Alkermes Plc will post $0.27 EPS for the current fiscal year.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.